SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics ...
For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ...
'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more ...
(MENAFN- GlobeNewsWire - Nasdaq) Published open-access today in Nature Genetics,“High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies ...